CardioExchange Archive

February 2nd, 2012

Study Explores Role of Periprocedural Dabigatran in AF Ablation

Larry Husten, PHD

As dabigatran becomes more widely used in AF patients, electrophysiologists are trying to figure out how to handle anticoagulation in patients taking the drug and for whom AF ablation is planned. In a new study published in the Journal of the American College of Cardiology, Dhanunjaya Lakkireddy and colleagues report on a multicenter, observational study of 290 patients […]

---

December 1st, 2011

Meta-Analysis Finds Benefits for Self-Monitoring in Some Warfarin Patients

Larry Husten, PHD

Despite the advent of newer anticoagulants that don’t require monitoring, millions of people will continue to take warfarin for many years to come. Now a new meta-analysis published in the Lancet suggests that some of these patients may benefit from self-monitoring. Carl Heneghan and colleagues analyzed data from 11 trials with 6417 patients on oral anticoagulation and 12,800 person-years […]

---

August 30th, 2011

Is Warfarin Still the First Choice in Atrial Fibrillation?

Stephen Fleet, MD

There’s an old maxim in medicine that one shouldn’t be the first to prescribe a new drug, nor the last. A fascinating debate between Michael Ezekowitz from the U.S. and Felicita Andreotti from Italy highlighted the differences between warfarin and the newer oral anticoagulants (NOACs) apixaban, rivaroxaban, and dabigatran. Even Dr. Ezekowitz, the warfarin protagonist for purposes […]

---

August 29th, 2011

ESC: A Closure Device and a Warfarin Substitute for High-Risk AFib Patients

Stephen Fleet, MD

How can we manage a patient with atrial fibrillation and contraindications to warfarin therapy such as recurrent severe bleeding — a common scenario in clinical practice? Data from the manufacturer-sponsored ASAP study (ASA Plavix Feasibility Study with WATCHMAN Left Atrial Appendage Closure Technology) provides some hope, beyond what we had learned from the Protect AF […]

---

August 28th, 2011

A “Straight A” Trial: Answers About Apixaban from ARISTOTLE

Samuel Goldhaber, MD

Several important questions about the relative safety and efficacy of apixaban versus warfarin in patients with nonvalvular atrial fibrillation have been answered.

---

August 24th, 2011

ARISTOTLE at ESC: What to Look for When the Data Are Unveiled

Samuel Goldhaber, MD

At 11:54 a.m. on August 28 in Paris (5:54 a.m. U.S. east coast time), I can almost imagine a huge drop in cell phone call volume as the ARISTOTLE presentation begins at ESC. The ESC exposition site is right next to Charles de Gaulle airport. Will a temporary “no fly zone” be declared? We know […]

---

July 14th, 2011

Rivaroxaban: The Next Non-Warfarin Oral Blood Thinner

John Mandrola, MD, FACC

An electrophysiologist and blogger places the recent approval of rivaroxaban in the context of the seismic changes that have taken place and that are still expected in the anticoagulant marketplace.

---

July 14th, 2011

Recurrent Arterial Thrombosis plus GI Bleeding in an Elderly Woman

Faiza Hashmi, MD and James Fang, MD

An 85-year-old woman with a history of hypertension and Crohn’s disease presented with severe pain in the left hand and was admitted to the hospital. Examination revealed a diminished left-radial pulse; arterial Doppler imaging showed a thrombus in the radial artery. The patient underwent surgical thrombectomy. The workup, including a hypercoagulability profile, was negative. Transthoracic […]

---

May 13th, 2011

Simultaneous TIA and ACS After Aspirin Cessation for Palpebral Surgery

Jean-Pierre Usdin, MD and James Fang, MD

A 77-year-old man with metformin-treated type 2 diabetes, high blood pressure, moderate renal insufficiency, stable angina, and a history of phlebitis stopped taking aspirin in preparation for palpebral surgery. A day after the surgery, he presented to the ER with two transient ischemic attacks (TIAs) affecting the left arm. The patient complained to the examining neurologist of […]

---

December 4th, 2010

Rivaroxaban Found Safe and Effective for DVT

Larry Husten, PHD

In the EINSTEIN-DVT noninferiority study, 3449 patients with acute DVT were randomized to receive open label oral rivaroxaban or conventional therapy with enoxaparin followed by warfarin or acenocoumarol for 3, 6, or 12 months. The rate of recurrent VTE, the primary efficacy outcome, was lower with rivaroxaban treatment than with enoxaparin treatment, successfully demonstrating noninferiority for […]

---